Aug 28 (Reuters) - Amgen Inc said it submitted an application to the U.S. Food and Drug Administration to market its cholesterol-lowering drug, evolocumab.
The injectable drug works by blocking PCSK9, a naturally occurring protein that keeps "bad" LDL cholesterol levels elevated in the bloodstream.
Other drugmakers, including Pfizer Inc, and a partnership between Regeneron Inc and Sanofi SA , are racing with Amgen to market potentially lucrative anti-PCSK9 antibodies.
(Reporting by Natalie Grover in Bangalore; Editing by Maju Samuel)
- Health Care Industry
- Pharmaceuticals & Drug Trials